Sana Biotechnology

### Executive Summary Sana Biotechnology raised $482.6M in a Regulation D private placement, with first sale on 2025-10-12. The company operates in synthetic biology and intracellular mRNA delivery, a capital-intensive frontier. The involvement of Lockheed Martin Ventures and Bessemer Venture Partners as related persons signals deep-tech and defense crossover interest. ### Investor Edge Watch for subsequent D/A amendments that could reveal additional investors or a higher total raise, signaling syndicate expansion. Also monitor for any public partnership announcements with Lockheed Martin or Bessemer portfolio companies in the mRNA delivery space. ### Sector capital positioning This $482.6M raise is one of the largest private synthetic biology rounds in recent years, indicating strong institutional appetite for intracellular mRNA delivery platforms. It reinforces a trend of defense and venture capital converging on programmable biology. ### Convergence Signals No explicit public signals (patents, contracts, legislation) are provided in the filing. However, Lockheed Martin Ventures' presence suggests potential defense or dual-use applications, which could align with DoD biomanufacturing initiatives or BARDA contracts. ### Key Takeaways - Sana Biotechnology raised $482.6M in a private placement, one of the largest in synthetic biology. - Lockheed Martin Ventures' involvement suggests potential defense or dual-use applications. - No public ticker or competitor tickers are directly linked; this is a private company. ### Risk Indicators & Flags No D/A amendments noted in this initial filing. However, the sector (synthetic biology) is capital-intensive and regulatory-heavy, posing execution risk. The absence of a public ticker limits liquidity for investors. ### Verification & References Verify filing details via SEC EDGAR using accession number 0001702600-24-20199. Confirm first sale date (2025-10-12) and capital raised ($482.6M) in the Form D. Related persons (Lockheed Martin Ventures, Bessemer Venture Partners) are listed as officers/directors per SEC rules.